Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 882

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance

Open access
Sati, Hatim, Carrara, Elena, Savoldi, Alessia, Hansen, Paul, Garlasco, Jacopo, Campagnaro, Enrica, Boccia, Simone, Castillo-Polo, Juan Antonio, Magrini, Eugenia, Garcia-Vello, Pilar, Wool, Eve, Gigante, Valeria, Duffy, Erin, Cassini, Alessandro, Huttner, Benedikt, Pardo, Pilar Ramon, Naghavi, Mohsen, Mirzayev, Fuad, Zignol, Matteo, Cameron, Alexandra, Tacconelli, Evelina, Aboderin, Aaron, Al Ghoribi, Majed, Al-Salman, Jameela, Amir, Afreenish, Apisarnthanarak, Anucha, Blaser, Martin, El-Sharif, Amany, Essack, Sabiha, Harbarth, Stephan, Huang, Xun, Kapoor, Geetanjali, Knight, Gwenan, Muhwa, Jeremiah Chakaya, Monnet, Dominique L., Ousassa, Timothée, Sacsaquispe, Rosa, Severin, Juliëtte, Sugai, Motoyuki, Taneja, Neelam, Umubyeyi Nyaruhirira, Alaine·2025·The Lancet Infectious Diseases

Abstract

BACKGROUND: The 2017 WHO Bacterial Priority Pathogens List (BPPL) has been instrumental in guiding global policy, research and development, and investments to address the most urgent threats from antibiotic-resistant pathogens, and it is a key public health tool for the prevention and control of antimicrobial resistance (AMR). Since its release, at least 13 new antibiotics targeting bacterial priority pathogens have been approved. The 2024 WHO BPPL aims to refine and build on the previous list by incorporating new data and evidence, addressing previous limitations, and improving pathogen prioritisation to better guide global efforts in combating AMR. METHODS: The 2024 WHO BPPL followed a similar approach to the first prioritisation exercise, using a multicriteria decision analysis framework. 24 antibiotic-resistant bacterial pathogens were scored based on eight criteria, including mortality, non-fatal burden, incidence, 10-year resistance trends, preventability, transmissibility, treatability, and antibacterial pipeline status. Pathogens were assessed on each of the criteria on the basis of available evidence and expert judgement. A preferences survey using a pairwise comparison was administered to 100 international experts (among whom 79 responded and 78 completed the survey) to determine the relative weights of the criteria. Applying these weights, the final ranking of pathogens was determined by calculating a total score in the range of 0-100% for each pathogen. Subgroup and sensitivity analyses were conducted to assess the impact of experts' consistency, background, and geographical origin on the stability of the rankings. An independent advisory group reviewed the final list, and pathogens were subsequently streamlined and grouped into three priority tiers based on a quartile scoring system: critical (highest quartile), high (middle quartiles), and medium (lowest quartile). FINDINGS: The pathogens' total scores ranged from 84% for the top-ranked bacterium (carbapenem-resistant Klebsiella pneumoniae) to 28% for the bottom-ranked bacterium (penicillin-resistant group B streptococci). Antibiotic-resistant Gram-negative bacteria (including K pneumoniae, Acinetobacter spp, and Escherichia coli), as well as rifampicin-resistant Mycobacterium tuberculosis, were ranked in the highest quartile. Among the bacteria commonly responsible for community-acquired infections, the highest rankings were for fluoroquinolone-resistant Salmonella enterica serotype Typhi (72%), Shigella spp (70%), and Neisseria gonorrhoeae (64%). Other important pathogens on the list include Pseudomonas aeruginosa and Staphylococcus aureus. The results of the preferences survey showed a strong inter-rater agreement, with Spearman's rank correlation coefficient and Kendall's coefficient of concordance both at 0·9. The final ranking showed high stability, with clustering of the pathogens based on experts' backgrounds and origins not resulting in any substantial changes to the ranking. INTERPRETATION: The 2024 WHO BPPL is a key tool for prioritising research and development investments and informing global public health policies to combat AMR. Gram-negative bacteria and rifampicin-resistant M tuberculosis remain critical priority pathogens, underscoring their persistent threat and the limitations of the current antibacterial pipeline. Focused efforts and sustained investments in novel antibacterials are needed to address AMR priority pathogens, which include high-burden antibiotic-resistant bacteria such as Salmonella and Shigella spp, N gonorrhoeae, and S aureus. Beyond research and development, efforts to address these pathogens should also include expanding equitable access to existing drugs, enhancing vaccine coverage, and strengthening infection prevention and control measures. FUNDING: This work is based on the development of the 2024 WHO BPPL, which was conducted by the WHO AMR Division through grants from the Government of Austria, the Government of Germany, the Government of Saudi Arabia, and the European Commission's Health Emergency Preparedness and Response Authority. TRANSLATIONS: For the Arabic, French, Italian, Japanese and Spanish translations of the abstract see Supplementary Materials section.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(25)00118-5

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Metadata

Authors
Sati, H., Carrara, E., Savoldi, A., Hansen, P., Garlasco, J., Campagnaro, E., Boccia, S., Castillo-Polo, J. A., Magrini, E., Garcia-Vello, P., Wool, E., Gigante, V., Duffy, E., Cassini, A., Huttner, B., Pardo, P. R., Naghavi, M., Mirzayev, F., Zignol, M., Cameron, A., Tacconelli, E., Aboderin, A., Al Ghoribi, M., Al-Salman, J., Amir, A., Apisarnthanarak, A., Blaser, M., El-Sharif, A., Essack, S., Harbarth, S., Huang, X., Kapoor, G., Knight, G., Muhwa, J. C., Monnet, D. L., Ousassa, T., Sacsaquispe, R., Severin, J., Sugai, M., Taneja, N., & Umubyeyi Nyaruhirira, A.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2025-09
Volume
25
Issue
9
Pages
1033-1043
ISSN
1473-3099 (ISSN-L)
OpenAlex
W4409430637
Cited by
882
References
14
FWCI
464.92
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. https://app.cochat.ai/papers/10.1016/s1473-3099(25)00118-5
The paper
Sati, H., Carrara, E., Savoldi, A., Hansen, P., Garlasco, J., Campagnaro, E., Boccia, S., Castillo-Polo, J. A., Magrini, E., Garcia-Vello, P., Wool, E., Gigante, V., Duffy, E., Cassini, A., Huttner, B., Pardo, P. R., Naghavi, M., Mirzayev, F., Zignol, M., . . . Umubyeyi Nyaruhirira, A. (2025). The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(25)00118-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.